Objective: The Pharmacology Shared Resource supports pharmacokinetic (PK) study planning and analysis for both basic and clinical research projects of University of Colorado Cancer Center (UCCC) members. Services and Technologies: Services offered include: (1) PK study design consultation;(2) Development, validation and implementation of appropriate analytical assays for drugs in biological fluids and tissues;and (3) PK modeling and mathematical analysis of analytical data. Quantitative analytical methods employed by the Pharmacology Shared Resource include UV/Vis and fluorescent detection HPLC, LC tandem mass spectrometry, and other biochemical methodologies (i.e. ELISA, enzymatic). PK modeling services include systems-based approaches (non-compartmental modeling), compartmental modeling, physiologically-based and population-based analyses. The Pharmacology Shared Resource, houses two ABI3200 linear trap triple quadropole instruments with LC systems (Agilent 1200 or Shimadzu LC20) and HTC-PAL autosamplers, a Shimadzu Prominence LC system with UV/Vis (SPD-M20A) and fluorescence detection (RF-IOAxl) and refrigerated autosampler (S1L20AC). Consultation: The Pharmacology Shared Resource provides consultation to help members with little pharmacology or PK background to design appropriate experiments and analyze PK data. Utilization: Cancer Center members in the Developmental Therapeutics Program are the primary users of the Pharmacology Shared Resource;however, members of the Hormone Related Malignancies, Lung, Head &Neck Cancer and Cancer Prevention &Control Programs are also regular users. The Pharmacology Shared Resource moved to CSU from the Anschutz Medical Campus in 2007 and since then, utilization by UCCC members has increased annually while use by non-UCCC members has remained constant. Since the last competitive application in 2005, the Pharmacology Shared Resource has supported 39 UCCC investigators from across the consortium institutions and 24 non-UCCC members. In the last two years, 14 research projects and 10 clinical protocols from UCCC members have been supported. Management and Finances: This resource is UCCC-managed. Currently, 73.5% of the operating budget comes from charge backs to UCCC members who represent 62% of facility users. The Pharmacology Shared Resource requests $115K CCSG support for 34% of its operating budget.

Public Health Relevance

The Pharmacology Shared resource gathers technology and expertise to fully support pharmacology aspects of UCCC members'preclinical or clinical research, including pharmacokinetic (PK) study design, analytical assay design and development appropriate for measuring drugs in biological samples, expertise in animal dosing and sampling, and PK modeling.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-24
Application #
8465413
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-06
Project End
2017-01-31
Budget Start
2012-08-06
Budget End
2013-01-31
Support Year
24
Fiscal Year
2012
Total Cost
$137,271
Indirect Cost
$46,587
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Maccini, Michael A; Westfall, Nicholas J; Van Bokhoven, Adrie et al. (2018) The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate 78:506-511
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6

Showing the most recent 10 out of 1634 publications